Loss of CCAAT ‐enhancer‐binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers

ConclusionsCEBPA is down regulated in about one third of prostate cancers, but the clinical impact of CEBPA loss is strictly limited to the subset of about 10% prostate cancers carrying bothERG fusion and deletions of thePTEN tumor suppressor. Our findings challenge the concept that prognostic molecular markers may be generally applicable to all prostate cancers.

Source: The Prostate - November 14, 2018 Category: Urology & Nephrology Authors: Sarah Minner, Jannes Lutz, Claudia Hube ‐Magg, Martina Kluth, Ronald Simon, Doris Höflmayer, Eike Burandt, Maria Christina Tsourlakis, Guido Sauter, Franziska Büscheck, Waldemar Wilczak, Stefan Steurer, Thorsten Schlomm, Hartwig Huland, Tags: ORIGINAL ARTICLE Source Type: research